Q1 2024 Earnings Estimate for Carisma Therapeutics, Inc. Issued By Capital One Financial (NASDAQ:CARM)

Carisma Therapeutics, Inc. (NASDAQ:CARMFree Report) – Analysts at Capital One Financial lifted their Q1 2024 earnings estimates for shares of Carisma Therapeutics in a research report issued on Tuesday, April 2nd. Capital One Financial analyst N. Quibria now expects that the company will post earnings of ($0.47) per share for the quarter, up from their prior forecast of ($0.48). The consensus estimate for Carisma Therapeutics’ current full-year earnings is ($2.13) per share. Capital One Financial also issued estimates for Carisma Therapeutics’ Q2 2024 earnings at ($0.45) EPS, Q3 2024 earnings at ($0.43) EPS, Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.82) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.09) EPS, FY2026 earnings at ($2.11) EPS and FY2027 earnings at ($2.12) EPS.

Separately, HC Wainwright reduced their target price on Carisma Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.60.

Check Out Our Latest Stock Report on Carisma Therapeutics

Carisma Therapeutics Stock Down 2.0 %

Shares of CARM opened at $1.97 on Thursday. The stock’s 50-day moving average price is $2.32 and its two-hundred day moving average price is $2.79. Carisma Therapeutics has a 12 month low of $1.86 and a 12 month high of $9.77. The company has a market capitalization of $81.83 million, a PE ratio of -0.57 and a beta of 0.95. The company has a current ratio of 7.53, a quick ratio of 7.53 and a debt-to-equity ratio of 0.01.

Institutional Trading of Carisma Therapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Carisma Therapeutics by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 1,568,761 shares of the company’s stock worth $4,596,000 after acquiring an additional 8,435 shares in the last quarter. Barclays PLC increased its position in shares of Carisma Therapeutics by 651.2% during the fourth quarter. Barclays PLC now owns 36,598 shares of the company’s stock valued at $107,000 after acquiring an additional 31,726 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in Carisma Therapeutics by 52.6% during the fourth quarter. Bridgeway Capital Management LLC now owns 311,034 shares of the company’s stock worth $911,000 after acquiring an additional 107,224 shares during the period. Northern Trust Corp grew its stake in Carisma Therapeutics by 21.1% in the 4th quarter. Northern Trust Corp now owns 238,916 shares of the company’s stock valued at $700,000 after purchasing an additional 41,644 shares during the period. Finally, American Century Companies Inc. purchased a new stake in Carisma Therapeutics during the third quarter worth about $67,000. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

(Get Free Report)

Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.

Recommended Stories

Earnings History and Estimates for Carisma Therapeutics (NASDAQ:CARM)

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.